此产品仅用于科学研究,我们不为任何个人用途提供产品和服务
Background:
Beta-Sheet Breaker Peptide iAβ5 (C33H43N5O8), with the sequence H-Leu-Pro-Phe-Phe-Asp-OH, has been shown to inhibit amyloidogenesis in rat brain models. Research showed that beta-sheet breaker peptide significantly reduces amyloid beta-protein deposition in vivo and completely blocks the formation of amyloid fibrils in a rat brain model of amyloidosis. Current evidence supports the notion that beta-amyloid deposits or Abeta intermediates may be responsible for the pathogenesis in Alzheimer’s disease (AD) patients. Because of its inhibition of cerebral amyloid beta-protein deposition, Beta-Sheet Breaker Peptide seems to be an important target for Alzheimer's disease therapy.
参考文献:
1. C. Soto, E.M. Sigurdsson, L. Morelli, R.A. Kumar, E.M. Castano, and B. Frangione, Nat. Med., 4, 822 (1998) (Original; Pharmacol.)
2. MA Chacon, MI Barria, C Soto and NC Inestrosa. Beta-sheet breaker peptide prevents Abeta-induced spatial memory impairments with partial reduction of amyloid deposits.
?
GnRH Associated Peptide (GAP) (1-13), human
¥354.00 ¥394.00
Amyloid Beta-Peptide (12-28) (human)
¥694.00 ¥772.00
Beta-Lipotropin (1-10), porcine
¥610.00 ¥678.00
Amyloid β-Peptide (10-20) (human)
¥963.00 ¥1071.00
Acetyl Angiotensinogen (1-14), porcine
¥424.00 ¥472.00
Melanocyte stimulating hormone release inhibiting factor
¥297.00 ¥331.00
PKA inhibitor fragment (6-22) amide
¥651.00 ¥724.00
没有评价数据